

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**POST-EFFECTIVE AMENDMENT NO. 1  
TO  
FORM F-1  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**AURIS MEDICAL HOLDING AG**  
(Exact name of Registrant as specified in its charter)

---

**Switzerland**  
(State or other jurisdiction of  
incorporation or organization)

**2834**  
(Primary Standard Industrial  
Classification Code Number)

**NOT APPLICABLE**  
(I.R.S. Employer  
Identification Number)

**Bahnhofstrasse 21  
6300 Zug, Switzerland  
+41 (0)41 729 71 94**  
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

---

**Agent for Service of Process  
National Corporate Research, Ltd.  
10 East 40th Street  
New York, New York 10016  
(212) 947-7200**  
(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**Richard D. Truesdell, Jr.  
Sophia Hudson  
Davis Polk & Wardwell LLP  
450 Lexington Avenue  
New York, NY 10017**

**Rachel W. Sheridan  
Latham & Watkins LLP  
555 Eleventh Street, NW, Suite 1000  
Washington, D.C. 20004**

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  333-197105

---



---

**EXPLANATORY NOTE**

This Post-Effective Amendment No. 1 to the Registration Statement on Form F-1 (File No. 333-197105) is filed pursuant to Rule 462(d) under the Securities Act of 1933, as amended (the "Securities Act"), solely to replace Exhibits 5.1 and 23.2 to such Registration Statement. This Registration Statement shall become effective upon filing with the Commission in accordance with Rule 462(d) under the Securities Act.

---

**PART II**

**INFORMATION NOT REQUIRED IN THE PROSPECTUS**

**Item 8. Exhibits and Financial Statement Schedules**

(a) The following documents are filed as part of this registration statement:

- 1.1\*\* Form of Underwriting Agreement
- 3.1\*\* Form of Articles of Association
- 4.1\*\* Form of Registration Rights Agreement
- 5.1 Opinion of Froriep, Swiss counsel of Auris Medical Holding AG, as to the validity of the common shares
- 8.1\*\* Opinion of Froriep, Swiss counsel of Auris Medical Holding AG, as to Swiss tax matters
- 8.2\* Opinion of Davis Polk & Wardwell LLP, as to U.S. tax matters
- 10.1†\* Collaboration and License Agreement, dated October 21, 2003, between Auris Medical AG and Xigen SA
- 10.2†\* Co-Ownership and Exploitation Agreement, dated September 29, 2003, between Auris Medical AG and INSERM
- 10.3\* Series C Investment Agreement, dated April 5, 2013
- 10.4\* Series C Shareholders' Agreement, dated April 5, 2013
- 10.5\* Convertible Loan Agreement, dated December 2013, between Auris Medical AG and Sofinnova Venture Partners VIII, L.P. and Sofinnova Capital VII FCPR
- 10.6\* Service Agreement, dated January 2011 between Auris Medical AG and Altamira Pharma GmbH
- 10.7\* Termination of Service Agreement, dated February 2014 between Auris Medical AG and Altamira Pharma GmbH
- 10.8\* Loan Agreement, dated January 2013 between Auris Medical AG and Altamira Pharma GmbH
- 10.9\*\* Form of Indemnification Agreement
- 10.10\* English language translation of Lease Agreement between Auris Medical AG and Privera AG
- 10.11\* Stock Option Plan A
- 10.12\* Stock Option Plan C
- 16.1\* Letter of KPMG AG, dated June 27, 2014, regarding change in the Company's independent registered public accounting firm
- 21.1\* List of subsidiaries
- 23.1\*\*\* Consent of KPMG AG
- 23.2 Consent of Froriep, Swiss counsel of Auris Medical Holding AG (included in Exhibit 5.1)
- 23.3\*\* Consent of Froriep, Swiss counsel of Auris Medical Holding AG (included in Exhibit 8.1)
- 23.4\* Consent of Davis Polk & Wardwell LLP (included in Exhibit 8.2)
- 24.1\* Powers of attorney (included on signature page to the registration statement)

\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on June 27, 2014.

\*\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on July 21, 2014.

\*\*\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on August 5, 2014.

† Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.

(b) Financial Statement Schedules

None.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Zug, Switzerland, on August 8, 2014.

Auris Medical Holding AG

By: /s/ Thomas Meyer

Name: Thomas Meyer

Title: Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on August 8, 2014 in the capacities indicated:

<u>NAME</u>	<u>TITLE</u>
<u>/s/ Thomas Meyer</u> Thomas Meyer	Chief Executive Officer and Director (principal executive officer)
<u>*</u> Sven Zimmermann	Chief Financial Officer (principal financial officer and principal accounting officer)
<u>*</u> Wolfgang Arnold	Director
<u>*</u> Alain Munoz	Director
<u>*</u> James I. Healy	Director
<u>*</u> Oliver Kubli	Director
<u>*</u> Antoine Papiernik	Director
<u>*</u> Colleen A. DeVries SVP of National Corporate Research, Ltd.	Authorized Representative in the United States
*By: <u>/s/ Thomas Meyer</u> Thomas Meyer As Attorney-in-Fact	

---

## EXHIBIT INDEX

The following documents are filed as part of this registration statement:

- 1.1\*\* Form of Underwriting Agreement
- 3.1\*\* Form of Articles of Association
- 4.1\*\* Form of Registration Rights Agreement
- 5.1 Opinion of Froriep, Swiss counsel of Auris Medical Holding AG, as to the validity of the common shares
- 8.1\*\* Opinion of Froriep, Swiss counsel of Auris Medical Holding AG, as to Swiss tax matters
- 8.2\* Opinion of Davis Polk & Wardwell LLP, as to U.S. tax matters
- 10.1†\* Collaboration and License Agreement, dated October 21, 2003, between Auris Medical AG and Xigen SA
- 10.2†\* Co-Ownership and Exploitation Agreement, dated September 29, 2003, between Auris Medical AG and INSERM
- 10.3\* Series C Investment Agreement, dated April 5, 2013
- 10.4\* Series C Shareholders' Agreement, dated April 5, 2013
- 10.5\* Convertible Loan Agreement, dated December 2013, between Auris Medical AG and Sofinnova Venture Partners VIII, L.P. and Sofinnova Capital VII FCPR
- 10.6\* Service Agreement, dated January 2011 between Auris Medical AG and Altamira Pharma GmbH
- 10.7\* Termination of Service Agreement, dated February 2014 between Auris Medical AG and Altamira Pharma GmbH
- 10.8\* Loan Agreement, dated January 2013 between Auris Medical AG and Altamira Pharma GmbH
- 10.9\*\* Form of Indemnification Agreement
- 10.10\* English language translation of Lease Agreement between Auris Medical AG and Privera AG
- 10.11\* Stock Option Plan A
- 10.12\* Stock Option Plan C
- 16.1\* Letter of KPMG AG, dated June 27, 2014, regarding change in the Company's independent registered public accounting firm
- 21.1\* List of subsidiaries
- 23.1\*\*\* Consent of KPMG AG
- 23.2 Consent of Froriep, Swiss counsel of Auris Medical Holding AG (included in Exhibit 5.1)
- 23.3\*\* Consent of Froriep, Swiss counsel of Auris Medical Holding AG (included in Exhibit 8.1)
- 23.4\* Consent of Davis Polk & Wardwell LLP (included in Exhibit 8.2)
- 24.1\* Powers of attorney (included on signature page to the registration statement)

\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on June 27, 2014.

\*\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on July 21, 2014.

\*\*\* Filed as part of this registration statement on Form F-1 (Registration no. 333-197105) on August 5, 2014.

† Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.

ZURICH  
GENEVA  
ZUG  
LAUSANNE  
LONDON  
MADRID

To:  
Auris Medical Holding AG  
Bahnhofstrasse 21  
6300 Zug  
Switzerland

Zurich, August 8, 2014  
10024177/448616v1

**Dr Ansgar Schott** | Partner  
aschott@froriep.ch

**Auris Medical Holding AG – Registration Statement on Form F-1**

Ladies and Gentlemen:

We have acted as Swiss counsel to Auris Medical Holding AG (the “**Company**”) in connection with the filing of a registration statement on Form F-1 filed on June 27, 2014 (Registration No. 333-197105), including the prospectus set forth therein (the “**First Registration Statement**”), as amended by the amendment No. 1 to the First Registration Statement filed on July 21, 2014 (the “**Amendment No. 1**”) and the amendment No. 2 to the First Registration Statement filed on August 5, 2014 (the “**Amendment No. 2**”, and the First Registration Statement, as amended by the Amendment No. 1 and the Amendment No. 2, the “**Registration Statement**”) for the purpose of registering under the United States Securities Act of 1933, as amended (the “**Securities Act**”) 9,400,000 common shares of CHF 0.40 par value each of the Company (the “**Shares**”), and any additional shares with a nominal value of CHF 0.40 sold or, if and to the extent such option is exercised, to be sold to the underwriters pursuant to the over-allotment option granted by the Company to the underwriters. As such counsel, we have been requested to render an opinion as to certain matters of Swiss law.

**1. Basis of Opinion**

This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof and as currently applied by the Swiss courts. In the absence of statutory or established case law, we base our opinion on our independent professional judgement.

This opinion is also confined to the matters stated herein and is not to be read as extending, by implication or otherwise, to any other matter.

FRORIEP | Attorneys at law  
Zurich | T +41 44 386 60 00

| Bellerivestrasse 201 | P.O. Box 385 | 8034  
| froriep.com



---

For the purpose of giving this opinion, we have only examined the following documents (the “**Documents**”):

- (i) a pdf copy of the First Registration Statement;
- (ii) a pdf copy of the Amendment No.1;
- (iii) a pdf copy of the Amendment No. 2;
- (iv) a pdf copy of the original certified articles of incorporation of the Company in their version of August 7, 2014 (the “**Articles**”);
- (v) a pdf copy of the original of the internal regulations (*Organisationsreglement*) of the Company in their version of July 4, 2014 (the “**Organizational Regulations**”);
- (vi) the original of a certified excerpt from the daily registry of the Commercial Register of the Canton of Zug dated August 8, 2014 relating to the Company (the “**Excerpt**”);
- (vii) a pdf copy of the notarized shareholders resolution passed at the extraordinary general meeting of shareholders of the Company held on July 14, 2014 regarding, among others, (a) the authorization (the “**Authorization**”) granted to the board of directors to increase the share capital up to CHF 3,760,000 divided into 9,400,000 shares of a nominal value of CHF 0.40 each and (b) the adoption of the Articles subject to the condition that the Authorization is exercised by the board of directors of the Company (the “**Shareholders Resolution**”);
- (v) a pdf of the resolution of the Company’s pricing committee dated August 5, 2014 approving the pricing terms and conditions (the “**Pricing Committee Resolution**”);
- (vi) a pdf copy of a circular resolution of the Company’s board of directors dated June 26, 2014 approving, among others, the execution of the underwriting agreement, such underwriting agreement to reflect the pricing terms and conditions as approved by the pricing committee, the listing of the shares of the Company on the NASDAQ, the offering and sale of the Shares as contemplated in the underwriting agreement (the “**Listing Board Resolution**”);
- (vii) a pdf copy of the report of the board of directors of the Company regarding the increase of the Company’s share capital by the amount of CHF 3,760,000 divided into 9,400,000 shares of a nominal value of CHF 0.40 each (the “**Capital Increase**”) (*Kapitalerhöhungsbericht*), dated August 7, 2014 (the “**Board Report**”);

- 
- (viii) a pdf copy of the notarized resolutions of the board of directors of the Company regarding the execution of the Capital Increase based on the Authorization and the relevant adoption of the amended Company's Articles (*Feststellungsbeschluss*) as well as the statement on the execution of the Capital Increase and the entry into force of the generally revised Company's Articles, dated August 7, 2014 (the "**Capital Increase Board Resolution**" and together with the Listing Board Resolution, the "**Board Resolutions**");
  - (ix) a pdf copy of certain declarations of the Company vis-à-vis the Commercial Register of the Canton of Zug (*Lex Friedrich- und Stampa-Erklärungen*), dated August 7, 2014 (the "**Declarations**");
  - (x) a pdf copy of the capital payment confirmation from UBS AG (*Kapitaleinzahlungsbestätigung*) regarding the transfer of CHF 3,760,000, to a blocked bank account, dated August 7, 2014 (the "**Bank Confirmation**");
  - (xi) pdf copies of the subscription forms (*Zeichnungsscheine*), dated August 6, 2014, July 25, 2014, July 23, 2014 and July 18, 2014 respectively, and signed on behalf of the relevant underwriter (the "**Subscription Forms**");
  - (xii) a pdf copy of the audit confirmation by Deloitte AG on the Board Report (*Prüfungsbestätigung*), dated August 7, 2014 (the "**Audit Confirmation**"); and
  - (xiii) a pdf copy of the Company's uncertificated securities book dated August 8, 2014 (*Wertrechtbuch*) confirming the creation of 28,241,275 uncertificated securities of the Company (the "**Securities Book**").

No documents have been reviewed by ourselves in connection with this opinion other than those listed above. Accordingly, our opinion is limited to the above Documents and their legal implications under Swiss law.

All terms used in this opinion in uppercase form shall have the meaning ascribed to them in the Registration Statement, unless otherwise defined herein. In this opinion, Swiss legal concepts are expressed in English terms and not in their original language. These concepts may not be identical to the concepts described by the same English language terms as they exist under the laws of other jurisdictions.

## 2. Assumptions

In rendering the opinion below, we have assumed:

- a) the conformity to the Documents of all documents produced to us as copies, fax copies or via e-mail, and that the original was executed in the manner appearing on the copy of the draft;

- 
- b) the genuineness and authenticity of the signatures on all copies of the original Documents thereof which we have examined, and the accuracy of all factual information contained in, or material statements given in connection with, the Documents;
  - c) the Shareholders Resolution, the Board Resolution and the Pricing Committee Resolution have been duly resolved in meetings duly convened and have not been rescinded or amended and are in full force and effect;
  - d) the Board Report, the Declarations and the Audit Confirmation have not been rescinded or amended and are in full force and effect, and the Bank Confirmation is correct as of the date hereof;
  - e) the First Registration Statement, the Amendment No. 1 and the Amendment No. 2 have been duly filed by the Company;
  - f) the Articles, the Organizational Regulations, the Excerpt and the Securities Book are unchanged and correct as of the date hereof and no changes have been made which should have been or should be reflected in the Articles, the Organizational Regulations, the Excerpt or the Securities Book as of the date hereof;
  - g) with regard to the Excerpt, a corresponding registration will be made in the main registry of the Commercial Register of the Canton of Zug relating to the Company, and the entering into force of the Company's Articles and the Capital Increase will be published in the Swiss Official Gazette of Commerce;
  - h) each Subscription Form is within the capacity and power of, and has been validly authorized and executed by and is binding on the relevant Underwriter; and
  - i) to the extent relevant for purposes of this opinion, all factual information contained in, or material statements given in connection with, the Documents are true, complete and accurate.

### **3. Opinion**

Based upon the foregoing and subject to the qualifications set out below, we are of the opinion that the Shares have been validly issued, fully paid-in (up to their nominal amount) and are non-assessable.

---

#### 4. Qualifications

The above opinions are subject to the following qualifications:

- a) The lawyers of our firm are members of the Swiss bar and do not hold themselves to be experts in any laws other than the laws of Switzerland. Accordingly, we are opining herein as to Swiss law only and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction.
- b) This opinion is based on the current provisions of the laws of Switzerland and the regulations thereunder in effect on the date hereof and only as currently interpreted in Switzerland. Such laws and their interpretation are subject to change.
- c) Notwithstanding the registration of the share capital with the Commercial Register of the Canton of Zug, the Shareholders Resolution underlying such share capital may be challenged by a dissenting shareholder in court within two months after the Shareholders Resolution. Should the court decide in the favor of the claimant, the court may annul the relevant resolution of the general meeting of the shareholders. As a consequence, any amendment made to the articles of incorporation of the company based on such a resolution may be void.
- d) When used in this opinion, the term “non-assessable” means that no further contributions have to be made by the relevant holder of the Shares.
- e) When used in this opinion, the term “validly issued” means that the issuance of the Shares is valid between the Company and the underwriters as the initial subscribers of the Shares.
- f) We express no opinion as to the accuracy or completeness of the information contained in the Registration Statement.
- g) We express no opinion as to any commercial, calculating, auditing or other non-legal matters. Further, we express no opinion as to tax law.

\* \* \*

We have rendered this opinion as of the date hereof and we assume no obligation to advise you of changes that may thereafter be brought to our attention.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading “Legal Matters” contained in the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

This opinion shall be governed by and construed in accordance with the laws of Switzerland.

---

Sincerely yours,

FRORIEP

/s/ Ansgar Schott

Dr Ansgar Schott